A library of new phenstatin based indole linked chalcone compounds (9a-z and 9aa-ad) were designed and synthesized. Of these, compound 9a with 1-methyl, 2- and 3-methoxy substituents in the aromatic ring was efficacious against the human oral cancer cell line SCC-29B, spheroids, and in a mouse xenograft model of oral cancer AW13516. Compound 9a exhibited anti-cancer activity through disrupting cellular integrity and affecting glucose metabolism-which is a hallmark of cancer. The cellular architecture was affected by inhibition of tubulin polymerization as observed by an immunofluorescence assay on 9a-treated SCC-29B cells. An in vitro tubulin polymerization kinetics assay provided evidence of direct interaction of 9a with tubulin. This physical interaction between tubulin and compound 9a was further confirmed by Surface Plasmon Resonance (SPR) analysis. Molecular docking experiments and validations revealed that compound 9a interacts and binds at the colchicine binding site of tubulin and at active sites of key enzymes in the glucose metabolism pathway. Based on in silico modeling, biophysical interactions, and pre-clinical observations, 9a consisting of phenstatin based indole-chalcone scaffolds, can be considered as an attractive tubulin polymerization inhibitor candidate for developing anti-cancer therapeutics.
Keywords: (18)F-fluorodeoxyglucose uptake; Anti-cancer efficacy; Cancer stem- like cells; Glucose metabolism; Immunofluorescence; In silico analysis; In vitro cell cytotoxicity; Laser confocal microscopy; Molecular docking; Multi-target metabolic inhibitor; Oral cancer xenograft model; PET-CT imaging; Phenstatin based indole-linked chalcones; Spheroid assay; Surface Plasmon Resonance; Transmission electron microscopy; Tubulin polymerization inhibition.
Copyright © 2020 Elsevier Inc. All rights reserved.